Zentiva Group a.s.

Zentiva has revealed the result of its previously-announced bid to take control of “single pill company” Apontis Pharma – and the outcome is positive for the buyer, with Zentiva’s voluntary public pur

Zentiva has responded to rumors that owner Advent could be looking to sell the firm, with a recent Bloomberg report suggesting that Advent is exploring options and valuing a potential deal at €5bn (

Zentiva has launched a bid to take control of Apontis Pharma through a voluntary public purchase offer that values the German branded player at €85m ($92.2m). Apontis – which bills itself as “the sing

Things may be looking up in the US for adalimumab biosimilars, but Coherus BioSciences, Inc. 's decision to divest Yusimry (adalimumab-aqvh) saw analysts raise questions on the wider prospects for ri